Alteogen said on the 20th that it signed a technology export deal worth 420 billion won with Tesaro, a subsidiary of GSK plc. Alteogen has technology that converts anticancer drugs from intravenous injections to subcutaneous injections. It plans to apply this technology to GSK's anticancer therapy dostarlimab (Jemperli).
Alteogen signed an exclusive license agreement with Tesaro for the development and commercialization of a subcutaneous formulation of dostarlimab using ALT-B4 technology. This technology breaks down the hyaluronic acid layer in subcutaneous tissue so the drug can be absorbed quickly. Tesaro will develop and commercialize the subcutaneous formulation of dostarlimab using Alteogen's technology.
Alteogen will receive an upfront payment of $20 million (29.5 billion won). Upon achieving development, marketing approval, and commercialization milestones, it will receive $265 million (390.5 billion won) in milestone payments. It will also receive separate royalties (a portion of sales revenue). Alteogen will handle ATL-B4 clinical trials and commercial product supply.
Chief Executive Jeon Tae-yeon of Alteogen said, "We have expanded the scope of technology application through collaboration with Tesaro," adding, "We hope the subcutaneous formulation therapy will be successfully developed and launched on the market."